ArticleBMC pulmonary medicine2024

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.

Hsu-Yuan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.